Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET
- More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA-1 Phase 3 clinical trial
- Cash position of €73.2 million ($82.2 million) at the end of 2019